Top 50 Medical Device VC Funds & Investors in Asia (October 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Qiming Venture Partners
VC Fund
|
29 | China, United States, Hong Kong | Series B, Series A, Series C | Health Care, Biotechnology, Medical | $4.3M–$120M |
|
HSG
VC Fund
|
15 | China, United States, Singapore | Series A, Series B, Seed | Artificial Intelligence, Software, Health Care | $2M–$200M |
|
Mitsubishi UFJ Capital
VC Fund
|
15 | Japan, United States, Israel | Series A, Venture - Series Unknown, Seed | Software, Information Technology, Manufacturing | $470k–$21M |
|
Cowin Capital
VC Fund
|
14 | China, United States, Hong Kong | Series A, Series B, Seed | Manufacturing, Health Care, Semiconductor | $1.4M–$51M |
|
IDG Capital
VC Fund
|
13 | China, United States, Singapore | Series A, Series B, Seed | Internet, Software, E-Commerce | $600k–$110M |
|
Lilly Asia Ventures
VC Fund
|
12 | China, United States, Hong Kong | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $14M–$308M |
|
Taiyu Investment
VC Fund
|
12 | China | Seed, Series A, Angel | Medical, Health Care, Biotechnology | $434k–$100M |
|
Shunwei Capital
VC Fund
|
12 | China, United States, India | Series A, Series B, Seed | Manufacturing, Software, Artificial Intelligence | $1M–$74M |
|
BioVenture
VC Fund
|
12 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $4.4M–$85M |
|
Addor Capital
VC Fund
|
11 | China, Hong Kong, United States | Series A, Series B, Venture - Series Unknown | Manufacturing, Semiconductor, Electronics | $1.4M–$145M |
|
Matrix Partners China
VC Fund
|
11 | China, United States, Singapore | Series A, Series B, Seed | Health Care, Software, Biotechnology | $1.2M–$137M |
|
CD Capital
VC Fund
|
11 | China, United States | Series A, Series B, Seed | Health Care, Biotechnology, Medical Device | $1.4M–$34M |
|
BioTrack Capital
VC Fund
|
10 | China, United States, Singapore | Series A, Series B, Seed | Biotechnology, Health Care, Medical | $14M–$168M |
|
BIOCHING CAPITAL
VC Fund
|
10 | China | Angel, Series A, Seed | Medical Device, Medical, Biotechnology | $433k–$15M |
|
Haibang Capital
VC Fund
|
9 | China | Series A, Series B, Angel | Health Care, Biotechnology, Manufacturing | $435k–$79M |
|
Prox Ventures
VC Fund
|
9 | China, United States, United Kingdom | Seed, Series A | Medical, Biotechnology, Health Care | $2.5M–$30M |
|
Northern Light Venture Capital
VC Fund
|
9 | China, United States, South Korea | Series A, Series B, Venture - Series Unknown | Health Care, Medical, Biotechnology | $1.5M–$60M |
|
ZhenFund
VC Fund
|
9 | China, United States, Singapore | Seed, Series A, Angel | Artificial Intelligence, Software, E-Commerce | $146k–$22M |
|
EFung Capital
VC Fund
|
9 | China, United States, India | Series A, Series B, Series C | Health Care, Biotechnology, Medical | $1.4M–$100M |
|
Oriza Seed Capital (Oriza Yuandian)
VC Fund
|
8 | China, United States, Singapore | Series A, Seed, Angel | Manufacturing, Health Care, Medical | $223k–$60M |
|
Dalton Venture
VC Fund
|
8 | China, India, Canada | Seed, Series A, Series B | Health Care, Medical, Biotechnology | $512k–$50M |
|
Fast Track Initiative, Inc.
VC Fund
|
8 | Japan, United States, United Kingdom | Series A, Series B, Seed | Health Care, Biotechnology, Medical | $345k–$117M |
|
JAFCO
VC Fund
|
8 | Japan, United States, India | Series A, Series B, Venture - Series Unknown | Information Technology, Software, Artificial Intelligence | $1.4M–$41M |
|
Nissay Capital
VC Fund
|
8 | Japan, United States, Ethiopia | Venture - Series Unknown, Seed, Series A | Health Care, Software, Medical | $455k–$12M |
|
Med-Fine Capital
VC Fund
|
8 | China, Hong Kong, United States | Series A, Seed, Series B | Medical, Health Care, Biotechnology | $3M–$60M |
|
Legend Capital
VC Fund
|
8 | China, United States, South Korea | Series B, Series A, Series C | Health Care, Medical, Biotechnology | $2.9M–$200M |
|
Nippon Venture Capital
VC Fund
|
7 | Japan, United States, Indonesia | Venture - Series Unknown, Series A, Series B | Software, Health Care, Medical | $457k–$45M |
|
UntroD Capital
VC Fund
|
7 | Japan, Singapore, Austria | Seed, Venture - Series Unknown, Series A | Manufacturing, Biotechnology, Health Care | $316k–$15M |
|
Shenzhen Capital Group
VC Fund
|
7 | China, United States, Japan | Series A, Series B, Seed | Manufacturing, Health Care, Software | $1.4M–$141M |
|
SND Ventures Group
VC Fund
|
7 | China | Series A, Series B, Seed | Manufacturing, Semiconductor, Health Care | $1.4M–$28M |
|
Sunland Fund
VC Fund
|
6 | China | Series A, Series B, Seed | Health Care, Medical, Medical Device | $1.4M–$28M |
|
Haiyuan Capital
VC Fund
|
6 | China | Series A, Seed, Angel | Manufacturing, Medical, Semiconductor | $432k–$15M |
|
Highlight Capital
VC Fund
|
6 | China, United States, South Korea | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $3.1M–$84M |
|
SZHTI Group
VC Fund
|
6 | China, Canada, United States | Series A, Angel, Series B | Manufacturing, Electronics, Health Care | $425k–$16M |
|
Share Capital
VC Fund
|
6 | China, United States, Colombia | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $161k–$93M |
|
Huagai Capital
VC Fund
|
6 | China, United States, Hong Kong | Series A, Series B, Angel | Health Care, Medical, Biotechnology | $425k–$90M |
|
Oriza Holdings
VC Fund
|
6 | China, United States, Canada | Series A, Series B, Seed | Manufacturing, Health Care, Biotechnology | $1.5M–$100M |
|
ANRI
VC Fund
|
6 | Japan, United States, Indonesia | Seed, Series A, Venture - Series Unknown | Software, Health Care, Information Technology | $268k–$41M |
|
Keio Innovation Initiative
VC Fund
|
6 | Japan, United Kingdom | Series A, Seed, Venture - Series Unknown | Health Care, Medical, Biotechnology | $826k–$41M |
|
Fortune Venture Capital
VC Fund
|
6 | China, Japan, United States | Series A, Series B, Seed | Manufacturing, Software, Information Technology | $462k–$73M |
|
SBI Investment
VC Fund
|
6 | Japan, United States, South Korea | Series B, Series A, Venture - Series Unknown | Software, Information Technology, Financial Services | $1.3M–$60M |
|
Marathon Venture Partners
VC Fund
|
6 | China, United States, Hong Kong | Series A, Series B, Seed | Health Care, Medical, Biotechnology | $1.5M–$142M |
|
Mizuho Capital
VC Fund
|
6 | Japan, United States, Singapore | Series A, Venture - Series Unknown, Series B | Information Technology, Software, Artificial Intelligence | $661k–$47M |
|
UTEC - The University of Tokyo Edge Capital Partners
VC Fund
|
5 | Japan, United States, India | Seed, Series A, Series B | Health Care, Biotechnology, Medical | $624k–$20M |
|
Huaige Capital
VC Fund
|
5 | China | Series A, Angel, Seed | Medical, Health Care, Biotechnology | $455k–$36M |
|
Tsinghua Innovation Ventures
VC Fund
|
5 | China | Venture - Series Unknown, Series A, Seed | Manufacturing, Medical, Health Care | $832k–$23M |
|
Apricot Capital
VC Fund
|
5 | China, United States, Hong Kong | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $3M–$58M |
|
CDH Investments
VC Fund
|
5 | China, United States, Canada | Series A, Series B, Series C | Manufacturing, Health Care, Biotechnology | $7.3M–$220M |
|
Seeds Capital
VC Fund
|
5 | Singapore, United States, Hong Kong | Seed, Series A, Series B | Biotechnology, Artificial Intelligence, Health Care | $767k–$45M |
|
FFG Venture Business Partners
VC Fund
|
5 | Japan, Indonesia, United States | Series A, Seed, Series B | Software, Health Care, Artificial Intelligence | $1M–$113M |
| Access all 50 VC funds in Asia Medical Device startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Founded in 2006, Qiming Venture Partners is a leading China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong in China, and Singapore.Currently, Qiming Venture Partners manages eleven US Dollar funds and seven RMB funds with $9.5 billion in capital raised. Since our establishment, we have invested in outstanding companiesin the Technology and Consumer (T&C) and Healthcare industries at the early and growth stages.Since our debut, we have backed over 530 fast-growing and innovative companies. Over 200 of our portfolio companies have achieved exits through IPOs at the NYSE, NASDAQ, HKEX, Shanghai Stock Exchange, or Shenzhen Stock Exchange, or through M&A or other means. There are also over 70 portfolio companies that have achieved unicorn or super unicorn status.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series B, Series A, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 1195
- Round size: Series A $4.3M–$48M; Series B $7.9M–$90M; Series C $12M–$120M
- Lead/follow: 51% lead, 49% follow
- Last fund: Likely actively investing — fresh fund, raised $8M in 2026
Portfolio highlights
- LP Amina — LP Amina focuses on products that improve coal-fired power plant's emissions and efficiency. Leveraging 50 unique patented products to improve the firing system of a coal-fired boiler, including Rotating Vane Wheels, High Performance Classifiers, Coal Pipe Balancing Technologies, and Burner Enhancements, the Company provides products andsolutions that will meet or exceed the expectations of their customers. Furthermore, LP Amina's corporate culture is one of a relentless pursuit of continuous improvement. Utilizing the latest technology and traditional know-how from the World's two largest users of Coal for power generation, the Company is well positioned to develop new products and solutions to meet the ever changing needs of Power Industry.LP Amina's staff has over 20 years of experience in the design, fabrication, installation and commissioning of coal-fired power plants. During this time, the team has gained a wide range of experience from the evolution of the US Power Market. Increases in environmental regulations and free market driven energy prices have forced plant operators to reduce emissions and improve reliability while lowering operational cost. LP Amina's engineering and design team will leverage this experience gained from the US and Europe to address the emergence of similar issues in China.
- Nice Tuan — Nice Tuan is an e-commerce platform that provides daily groceries and miscellaneous products.
- Shennapsi Artificial Intelligence Technology — Synapsor is a medical-grade wearable device research and development company, oriented to the AI+ medical and health field, and is committed to the development and manufacturing of AI-powered medical-grade smart wearable devices, including AI-ECG artificial intelligence. Diagnostic analysis system, CUMS uric acid blood glucose and cholesterolmonitoring system, etc. The company has recently received tens of millions of yuan in Series B investment, and the investor is Xiaomi Technology.
HSG is a leading venture capital and private equity firm investing globally in the technology, healthcare, and consumer sectors.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, Health Care
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 1085
- Round size: Seed $2M–$50M; Series A $4M–$100M; Series B $11M–$200M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $2.5B in 2024
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Suisheng Technology — Suisheng Technology is an innovative company specializing in AI-driven memory services, dedicated to developing intelligent solutions that help individuals and businesses capture, organize, and retrieve important information with greater efficiency and precision.
Mitsubishi UFJ Capital is a venture capital firm focusing on life science, ICT, and high technology investments.
Show more...Investment focus
- Industry: Software, Information Technology, Manufacturing
- Stage:Series A, Venture - Series Unknown, Seed
- Geography: Japan, United States, Israel
Investor stats
- Total investments: 685
- Round size: Seed $470k–$16M; Series A $1.2M–$21M; Venture - Series Unknown $525k–$11M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — raised $94M in 2020
Portfolio highlights
- Caguuu — Caguuu offers high-quality designer furniture at affordable prices, through e-commerce, eliminating middlemen and store operating costs.
- Smart Craft —
- Link Therapeutics — Link Therapeutics specializes in developing therapeutic methods for targeting autoantibodies and identifying pathogenic autoantibodies.
Cowin Capital is a private placement equity investment company focusing on investing in a pioneering enterprise on a long-term basis. It has 18 years of experience in capital management, whose capital management scale was among the front rank, which invested more than 300 companies, of which 60 more became public companies, and 150 moresuccessfully exit.The company was successfully listed on NEEQ, with code 832793, as the third listed famous domestic venture capital institution in NEEQ. It is committed to supporting the growth of small and medium enterprises, continue to launch high-quality listed companies in China Capital Market.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Semiconductor
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 366
- Round size: Seed $1.4M–$20M; Series A $2.8M–$51M; Series B $7.2M–$44M
- Lead/follow: 46% lead, 54% follow
- Last fund: May invest from a new fund soon — raised $75M in 2014
Portfolio highlights
- Bytetree — Bytetree is a technology company that focuses on providing the one-stop AI data services for data collection, cleaning, labeling, management, and storage for OEMs and autonomous driving solution providers, covering bicycle intelligence. , vehicle-road coordination, and smart cockpit three scenarios.
- Digital China — Digital China is a robotics company focused on developing humanoid interactive robots that can break traditional boundaries and create emotionally resonated partners.
- Loxun Kuangteng — Longxun Kuangteng injects computing technology, simulation methods, and mathematical algorithms into powerful material simulation tools to help researchers. They develop a software and hardware integration solution to provide customers with a range of services and support. They also provide customers with training, cooperation meetings, and otherservices.
IDG Capital is a global investment firm partnering with founders to build enduring businesses through capital, expertise, and long-term support.
Show more...Investment focus
- Industry: Internet, Software, E-Commerce
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 1220
- Round size: Seed $600k–$44M; Series A $2M–$100M; Series B $6.2M–$110M
- Lead/follow: 38% lead, 62% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Naive.ai — Naive.ai is a startup specializing in training AI agents with open-source models. It emphasizes post-training of open-source models to develop advanced AI agents.
- Arrow Yuan Technology — Arrow Yuan Technology focuses on the research and development of reusable stainless steel propellant tanks.
- Apex Intelligence — Apex Intelligence develops self-evolving AI models for scientific discovery.
Lilly Asia Ventures (LAV) is a leading biomedical venture capital firm headquartered in China, with offices in Shanghai, Hong Kong, and Palo Alto.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 253
- Round size: Series A $14M–$100M; Series B $25M–$110M; Series C $30M–$308M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $40M in 2019
Portfolio highlights
- InventisBio — InventisBio is a biotech company whose product pipeline includes small molecule drug candidates for targeted therapies in lung cancer, breast cancer and gout. The company is also actively developing drugs that can be combined with other immune-oncology targeted therapies, such as PD-1 antibody, for various cancer indications. The company isco-founded by Dr. Yaolin Wang and other scientists who have previously worked at Merck and Schering-Plough, leading various drug discovery projects in oncology, metabolic and infectious disease areas.
- NeuShen Therapeutics — We are a global biotech company committed to developing new and effective therapies for psychiatric and neurological disorders affecting millions of patients in need.
- Connexus Therapeutics — Connexus Therapeutics is a private, venture-backed biotechnology startup.
Taiyu Investment is an investment firm.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Series A, Angel
- Geography: China
Investor stats
- Total investments: 49
- Round size: Seed $2.8M–$20M; Angel $434k–$100M; Series A $13M–$29M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- Immunocan — Immunocan focuses on the development of fully human antibody animals, artificial chromosome carriers with independent intellectual property rights, focusing on tumor treatment, and developing antibody therapeutic drugs.
- Rhino Medical — Rhino Medical develops advanced technologies with independent intellectual property rights. The founding team has rich experience in R&D, marketing, and clinical. On the basis of benchmarking imported phacoemulsification instruments and vitrectomy instruments
- Infineon Multiomics — Infineon Multiomics is a biotechnology company that provides research and application of space multiomics technology.
Shunwei Capital is a venture capital fund that focuses on early to mid-stage investments in local internet industry. It specializes in incubation, startups, early to mid-stage, and growth capital investments. It seeks to invest in the technology, media, telecommunications, high technology, new media, games, internet finance, and rural area internetsectors. Their investors include sovereign wealth funds, fund of funds, university endowment funds, and family offices.
Show more...Investment focus
- Industry: Manufacturing, Software, Artificial Intelligence
- Stage:Series A, Series B, Seed
- Geography: China, United States, India
Investor stats
- Total investments: 616
- Round size: Seed $1M–$74M; Series A $1.5M–$41M; Series B $8.2M–$55M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $1.2B in 2018
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Sleptay — Sleptay is an innovative biopharmaceutical company, developing next-generation therapies for central nervous system diseases.
- Baiyue Interlink — Baiyue Interlink is a commercial aerospace company capable of reusable Level 1 and Level 2 space transportation.
Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greaterdevelopment space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 192
- Round size: Seed $7.9M–$41M; Series A $4.4M–$47M; Series B $7.1M–$85M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — raised $204M in 2016
Portfolio highlights
- Inno Medicine — Inno Pharmaceutical Technology specializes in research on the pathogenesis of atherosclerosis. The company focuses on the development of targeted nanoliposomes, targeting molecules with independent intellectual property rights, and currently focuses on the plaque reversal treatment of atherosclerosis.
- Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
- MyoGene Life Sciences — MyoGene Life Sciences is a regenerative medical company that specializes in the promotion of its regenerative repair material product line for bone repair.
Addor Capital offers investment services by financing early stage ventures and holding securities of other companies.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Electronics
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 363
- Round size: Series A $1.6M–$30M; Series B $12M–$145M; Venture - Series Unknown $1.4M–$101M
- Lead/follow: 50% lead, 50% follow
- Last fund: May invest from a new fund soon — raised $241M in 2021
Portfolio highlights
- Ibeki — Ibeki provides tiny photoelectric displacement sensors and servo control systems. eBridge uses the high precision and miniaturization of its precision motion drive technology to provide customers with a more complete technology portfolio, and has successfully transformed its core technology into a number of military and civilian products,particularly in aerospace, medical equipment, and intelligent control.
- Deep Blue Aerospace — Deep Blue Aerospace is a commercial carrier rocket developer.
- Ruimeng Semiconductor — Ruimeng Semiconductor is a provider of intelligent human-machine interface processor chips and solutions.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Matrix Partners China builds long-term relationships with entrepreneurs and helps them build significant, industry-leading companies.Since its inception in 1977, Matrix Partners China has made hundreds of investments and played an active role in the development of many successful businesses, 50 of which went on to IPO, and 75 of which have goneon to profitable M&A events. The firm consistently ranks in the top venture firms in terms of returns to its investors.Matrix Partners China combines local knowledge with global experience and vision. Its team consists of both former entrepreneurs and experienced investors. Its past successes include Focus Media, Eachnet, and Baidu, among others. The company invests across multiple sectors and stages.
Show more...Investment focus
- Industry: Health Care, Software, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 706
- Round size: Seed $1.2M–$74M; Series A $2.9M–$52M; Series B $10M–$137M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely still investing — raised $92M in 2023
Portfolio highlights
- Camera360 — Camera360 is a professional but easy-to use App for photo editing and selfie retouching. Tag #camera360
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Liepin — Liepin is the largest and most professional high-end talent community-based recruitment site, with its innovative products and unique service model model for create an interactive high-end talent recruitment platform between business, headhunting and workplace. Tens of thousands of professional executive search consultant for businesses and jobseekers set up communication between the bridge and accelerate corporate recruitment process, recommended paying jobs in the workplace, career development planning. 16 job seekers to avoid the risk of privacy protection, millions of high-end elite member libraries, help enterprises development needs.
CD Capital is a venture capital firm specialized in life sciences and medical technology. They are currently managing both RMB and USD funds with total size of $600M. CD Capital is operated by a professional team with diversified and profound industry backgrounds. They have made over 40 investments with high growth potential and earned a reputationas a premier venture capital firm with main focus on China healthcare industry. With broad network around China and the world, they have been able to seize the global trend, capture investment opportunities as well as help to define the future for China healthcare industry. Ultimately, they strive to grow best-in-class companies and deliver solid financial return to their investors.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China, United States
Investor stats
- Total investments: 73
- Round size: Seed $1.4M–$15M; Series A $1.5M–$32M; Series B $7.6M–$34M
- Lead/follow: 37% lead, 63% follow
Portfolio highlights
- Genlight — Genlight develops innovative treatment solutions for epilepsy and other neurological diseases. Genlight is headquartered in Hangzhou, China.
- Pipi Bear — Pipi Bear is a creator of living robots and health goods, with a focus on those that improve the lives of the elderly.
- CORE Biomedicine — CORE Biomedicine is a private, preclinical-stage biotechnology company that specializes in drug discovery and development for oncology.
BioTrack Capital invests in early and growth stage companies within life sciences, healthcare technology, biotechnology and related high-tech sectors, providing capital and investment support for innovation. The firm evaluates scientific and commercial potential of ventures and structures financings aimed at advancing technologies from earlyresearch to market engagement. Its activities include sourcing opportunities, conducting due diligence, and working with founders and management teams to align growth strategies with investor objectives. BioTrack Capital also participates in funding rounds alongside co-investors to support development of novel healthcare and tech solutions. The company engages with portfolio companies through strategic interaction and monitoring of progress toward business milestones.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Seed
- Geography: China, United States, Singapore
Investor stats
- Total investments: 94
- Round size: Seed $15M–$168M; Series A $14M–$45M; Series B $15M–$147M
- Lead/follow: 32% lead, 68% follow
Portfolio highlights
- Taiyi Quantum — Taiyi Quantum is dedicated to encouraging innovation in the distribution and implementation of quantum computing technology, as well as developing sophisticated quantum algorithms and delivering tailored computing solutions for businesses and research institutes.
- Convergen — Convergen develops TrimTAC, a targeted protein degradation platform for treating neurodegenerative diseases and other conditions driven by protein aggregates
- Zhiyue Space Intelligence — Zhiyue Space Intelligence specializes in robotic brain and brain systems.
BIOCHING CAPITAL is an investment management firm.
Show more...Investment focus
- Industry: Medical Device, Medical, Biotechnology
- Stage:Angel, Series A, Seed
- Geography: China
Investor stats
- Total investments: 22
- Round size: Angel $433k–$15M; Series A $14M–$14M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- Lunke Medical — Lunke Medical focuses on the research, development, production, and sales of medical devices, with particular strength and expertise in high-pressure technologies. The company is committed to delivering safe, reliable, and innovative solutions by combining advanced engineering, strict quality control, and continuous technological advancement tomeet the evolving needs of the medical industry.
- Rittal Medical — Rittal Medical is a reputable, large-scale Chinese manufacturer of animal imaging equipment with an emphasis on research, development, and production.
- Moer New Materials — Moer New Materials provides filtering membranes for the biopharmaceutical and semiconductor sectors.
Zhejiang Haibang Investment Management Co., Ltd. (also referred as "Haibang Capital") is an investment company focusing on venture capital and private equity. It was established in 2011 in Hangzhou. It was founded by Naxin Yao, the CEO of Focused Photonics, Inc (300203), a number of returnee entrepreneurs and experienced investmentprofessionals. In 2011, Haibang Capital launched its first Haibang Fund (formerly called “Haibang Talent Fund”) which was the first venture capital in China helping new returnees to start their own businesses. It is also a fund connect capital and "Thousand Talent Program" in Zhejiang Province. Haibang Capital keeps working on helping enterprises grow rapidly and build leading edge in their industry. In addition to providing capitals, Haibang Capital provides its investee companies with personalized value-added services, helping create both good economic and social benefits.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Manufacturing
- Stage:Series A, Series B, Angel
- Geography: China
Investor stats
- Total investments: 50
- Round size: Angel $435k–$2.8M; Series A $1.5M–$15M; Series B $10M–$79M
- Lead/follow: 20% lead, 80% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- MatriQ —
- Hopstem — Hopstem is a Hangzhou-based pharmaceutical company, engaged in human iPSCs/ESCs neural differentiation, cell banking, and cell engineering.
- Hongde New Materials — Hongde New Materials produces thermoplastic composite materials with fiber reinforcement. It offers energy storage and auxiliary components for solar and automobile power and steering systems.
Proxima Ventures focuses in the healthcare industry, supporting outstanding enterprises with innovative technologies or service models that have tremendous potential.They manage multiple funds in RMB and US dollar, covering from seed to growth stages. Their team members with multidisciplinary backgrounds and resourceful networks, have many yearsof remarkable venture capital experience and achievements. They believe that active and effective collaboration with entrepreneurs will make substantial economic returns while bring meaningful improvements in public health.
Show more...Investment focus
- Industry: Medical, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: China, United States, United Kingdom
Investor stats
- Total investments: 83
- Round size: Seed $2.5M–$30M; Series A $3M–$28M
- Lead/follow: 18% lead, 82% follow
Portfolio highlights
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Bluesail Surgical — Bluesail Surgical is a surgical device company that specializes in the development of innovative surgical instruments for cardiovascular and cerebrovascular treatments.
- Kingsung Medical Group — Kingsung Medical Group operates under the Mission “Simplify Surgery, Beautiful Life,” with its innovation centered on four core technology platforms at its Tianjin base: Mechanical Design, Polymer Materials, Biodegradable Magnesium Alloys, and Collagen Biomaterials. These platforms have enabled the development of pioneering medical devices,including microvascular anastomosis devices and neural tube. In particular, the Group’s biodegradable magnesium alloy technology is spearheading the advancement of next-generation orthopedic implants. Kingsung’s technological capabilities are evidenced by a portfolio of over 190 patents and its recognition as a National Key Enterprise. The Group also actively contributes to the industry as a standing council member of the Microsurgery Branch of the China Association of Medical Devices Industry and a member of the Chinese Society for Biomaterials.
Supporting the next generation of entpreneurs in enterprise, healthcare, and consumer with disruptive potential.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: China, United States, South Korea
Investor stats
- Total investments: 397
- Round size: Series A $2.9M–$40M; Series B $8.8M–$56M; Venture - Series Unknown $1.5M–$60M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $375M in 2021
Portfolio highlights
- Flytech — Flytech specializes in crystal materials and related components for magneto-optical-electrical integrated signal processing.
- Moge Microflow — Moge Microflow is a manufacturer of equipment for microreactors. It provides continuous flow production technologies and equipment for nanomaterials, pharmaceutical intermediates, and fine chemicals, as well as standardized high-end microreactor equipment.
- Bianzhong New Materials — Bianzhong New Materials is a high-tech company that specializes in the research and development of equipment for weaving and shaping three-dimensional preforms of high-strength fiber composite materials.
ZhenFund is a seed fund founded by former entrepreneurs to invest in the most promising innovators. New Oriental co-founders Bob Xiaoping Xu and Victor Qiang Wang established ZhenFund in 2011 in collaboration with Sequoia Capital China. ZhenFund now has a network of over 800 portfolio companies, including over 30 unicorns based in China. Webelieve that great businesses start with exceptional founding teams. We are dedicated to helping our entrepreneurs build successful companies by providing them with mentorship and the best resources available. Some of our services include biannual demo days to top Chinese VCs, ZhenHR services, marketing and PR consulting, as well as fundraising. Our strong and large CEO network also facilitates entrepreneurs helping each other, especially via our WeChat platform. ZhenFund has been ranked as the “#1 Early-Stage Investment Firm” for six years. Bob Xiaoping Xu, Founder of ZhenFund, has been named on the Midas List since 2016 and ranked #11 in 2019. Anna Fang, Founding Partner and CEO of ZhenFund, has been named on the Midas List since 2019 and made her 4th appearance as #12, and #1 on Midas Seed List in 2022.
Show more...Investment focus
- Industry: Artificial Intelligence, Software, E-Commerce
- Stage:Seed, Series A, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 751
- Round size: Seed $146k–$14M; Angel $425k–$3M; Series A $873k–$22M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — raised $140M in 2022
Portfolio highlights
- Snowplus — SNOWPLUS is an e-cigarette brand that provides users with e-cigarette products through a combination of online and offline sales models. The products are available in 12 different types of flavors. The products use TrueFeel honeycomb ceramic atomization technology and Aeroflow intake. Technology; In addition to reference to the existing food-gradestandards in China, Xuejia has also passed a number of third-party certifications in terms of safety. The core components such as atomizing core and cigarette holder comply with the highest medical safety standards of the FDA and the European Union.
- Futuring Robot — Futuring Robot is a developer of dual-arm home service robots focusing on C-end home scenarios.
- Qisuan Kuang-Chi — Qisuan Kuang-Chi is a pioneering artificial intelligence hardware company focusing on the research, development, and engineering of AI optical computing chips and related system infrastructure. The company utilizes a proprietary all-optical interference technology architecture to bypass physical constraints found in legacy electronic chipsets,aiming to establish computational infrastructure for Artificial General Intelligence (AGI).
Shenzhen EFUNG Investment Management Enterprise L. P. is one of China's earliest institutions investing in professional biomedical industries. Their strong research team and great investment returns made us won 'The Most Pioneering VC Institution” 'The Most Dynamic Pharmaceutical VC Institution in China' and 'The Top Ten VCInstitutions in Shenzhen'. With this influence, EFUNG has drawn a lot of attention from the medical and life science industry. And it is interviewed by Nature, which is the most authoritative science magazine in the world. Over a decade of years, they have been focusing on the medical and health industry, especially the VC and PE investment business of novel drugs and high-end medical devices. The mission of EFUNG is to drive the industrialization of medical researches by capital and to gain rich returns to investors. EFUNG has deeply screened and invested in more than 20 domestic and international premium enterprises, such as Chipscreen Biosciences, Frontier Biotechnologies, Ascentage Pharma, Lifotronic, Aridis Pharmaceuticals, and Centrexion.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Series C
- Geography: China, United States, India
Investor stats
- Total investments: 85
- Round size: Series A $1.4M–$36M; Series B $14M–$100M; Series C $14M–$74M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Xinyun Life — Xinyun Life Sciences is a high tech medical enterprise focusing on the R&D and industrialization of artificial intelligence vascular intervention devices. The company integrates AI deeply into its hardware development using a unique dual closed- oop system.
- Glimmer Gene — Glimmer Gene develops a comprehensive gene editing and epigenetic toolkit with independent intellectual property rights.
- Yuewei Medical — Yuewei Medical is a developer of cardiac surgery interventional medical devices.
Oriza Seed Venture Capital, located in Suzhou Industrial Park, is held by Suzhou Oriza Holdings Ltd. Oriza Seed is a market-oriented investment platform. It looks for investment opportunities among early-stage and growth-stage enterprises in the fields of Healthcare and TMT. Oriza Seed has ample resources and experiences investing in the healthcarefield. By late March 2016, Oriza Seed has invested in more than 50 healthcare companies, including Ascentage Pharma, Innovent Biologics, and SceneRay Corporation.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Medical
- Stage:Series A, Seed, Angel
- Geography: China, United States, Singapore
Investor stats
- Total investments: 153
- Round size: Seed $223k–$25M; Angel $425k–$15M; Series A $1.4M–$60M
- Lead/follow: 29% lead, 71% follow
Portfolio highlights
- Diver Innovation — Diver Innovation centers on intelligent cross-medium unmanned aerial vehicles.
- Navi Therapeutics — Navi Therapeutics is a biotechnology company focused on developing next-generation antibody-drug conjugates and antibody-based therapeutics for oncology
- Thortime Technology — Thortime Technology is a hard-tech company specializing in the full-stack development, manufacturing, and delivery of Neutral Beam Injection systems for controllable nuclear fusion devices.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Dalton Venture is a fund management company that specializes in early stage investment and industrial mergers and acquisitions in the field of big health.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Seed, Series A, Series B
- Geography: China, India, Canada
Investor stats
- Total investments: 143
- Round size: Seed $512k–$5M; Series A $3M–$17M; Series B $3.2M–$50M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Vibronix — Vibronix innovates for Precision Healthcare with spectroscopic imaging, optical & acoustic sensing, and machine learning.
- PowerMicro — PowerMicro focuses on the cutting-edge interdisciplinary field of “stem cells + engineered scaffolds,” specializing in the application of iPSC technology to advance regenerative medicine, tissue engineering, and innovative therapeutic solutions.
- NewPro — NewPro is in the process of increasing production and establishing regulations for lactoferrin raw materials, with the goal of bringing the product to market as quickly as feasible.
Fast Track Initiative is a venture capital firm with an exclusive focus on life sciences and healthcare services.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B, Seed
- Geography: Japan, United States, United Kingdom
Investor stats
- Total investments: 85
- Round size: Seed $345k–$117M; Series A $3M–$51M; Series B $4.7M–$83M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $124M in 2021
Portfolio highlights
- RegCell — RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer .
- NovAccel — NovAccel operates as a deep tech company, ensure a stable supply of medical radioisotopes.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Since its founding in 1973, JAFCO has always worked with leading-edge entrepreneurs. The total capital commitments of its investment funds in Japan and overseas have exceeded 1 trillion yen and the number of portfolio IPOs to date has reached over 1,000. In addition to venture investment, JAFCO also carries out buyout investment and commit to thecreations of innovative technologies and services worldwide. As entrepreneurs’ closest partner in bringing their visions to life, JAFCO provides support in areas of HR, marketing/ sales, and back-office operations, in addition to providing financing.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Series B, Venture - Series Unknown
- Geography: Japan, United States, India
Investor stats
- Total investments: 366
- Round size: Series A $2.1M–$41M; Series B $4.2M–$36M; Venture - Series Unknown $1.4M–$13M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $567M in 2019
Portfolio highlights
- CaTe — CaTe is based in Tokyo. CaTe develops and manufactures a Digital Therapeutic (DTx) for remote cardiac rehabilitation. Their invention allows heart disease patients to safely and successfully complete cardiac rehabilitation utilizing standing exercise in a confined space, such as at home, without the use of ergometers or similar instruments.
- Alxtal — Alxtal is a tech company who optimize the development, design, and manufacturing processes of the manufacturing industry with IT and AI.
- EISHIN — EISHIN is a technology company that specializes in pet tech business, recruitment consulting, website creation, and development services.
Nissay Capital is a venture capital Company specializing in seed, start-up, growth capital, middle stage, and later stage investment.
Show more...Investment focus
- Industry: Health Care, Software, Medical
- Stage:Venture - Series Unknown, Seed, Series A
- Geography: Japan, United States, Ethiopia
Investor stats
- Total investments: 324
- Round size: Seed $455k–$9.6M; Series A $1.2M–$12M; Venture - Series Unknown $899k–$7M
- Lead/follow: 29% lead, 71% follow
- Last fund: May invest from a new fund soon — raised $92M in 2019
Portfolio highlights
- OptQC — OptQC commercializes cutting-edge optical quantum computing technologies developed by the Furusawa-Endo Laboratory. Because optical quantum computers are more scalable than superconducting and other quantum computing implementations, OptQC's optical quantum computers should reach this scale. They also have benefits like faster processing andreduced power consumption, which makes optical quantum computers a possible long-term pinnacle of quantum technology.
- Eight Knot — Eight Knot is a developer of autonomous navigation systems intended for water mobility. They provide autonomous ship maneuvering technology using robotics, enabling customers with water-on-demand transportation using environment-friendly EV robotic boats.
- Zeal Boxing Fitness — Zeal Boxing Fitness combines power of sports with the power of technology to provide a service that allows to enjoy fitness.
Med-Fine Capital is a venture capital firm focusing on early stage investments in China healthcare industry. The company is headquartered in Shanghai with offices in Beijing and Shenzhen.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Seed, Series B
- Geography: China, Hong Kong, United States
Investor stats
- Total investments: 83
- Round size: Seed $8M–$60M; Series A $3M–$40M; Series B $12M–$60M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $73M in 2019
Portfolio highlights
- Zhuanma Biotech — Zhuanma Biotechnology is a gene editing service provider dedicated to clinically developing effective ultra-small gene editors into genetic therapeutics that are "curable once and for all."
- Tianyikang Biotechnology — Tianyikang Biotechnology focuses on medical research and the development and application of next-generation cell immunotherapy products.
- Beijing Ansong Technology — Beijing Ansong Technology Co., Ltd. is an enterprise focusing on the research and development, production, and sales of orthopedic medical devices. The company cooperates with domestic and foreign universities, research institutes, and doctors in hospitals, and is committed to creating original orthopedic products with independent knowledgeproducts.Beijing Ansong Technology was founded on June 27, 2011 by Liang Tao in Fengtai, Beijing.
Legend Capital, a subsidiary of Legend Holdings Ltd., started its vintage year in April, 2001 with a mission to become a top-notch and the most respected venture capital investment manager in China.Managing up to US$700 million across four funds, Legend Capital focuses on driving high-growth ventures with operations substantially based in Chinaor on markets related to China.Legend Capital mainly invests in early stage IT companies, specifically, in sectors of network applications and services, outsourcing and professional services, Infrastructure (IC design/key components), and mid-market growth stage companies in the fields of consumer goods, clean technology, health care, equipment manufacturing and modern services.Among over 60 portfolio companies are Joyo.com (acquired by Amazon.com), SinoCom (0299.HK), Solarfun Power (Nasdaq: SOLF), Spreadtrum Communications (Nasdaq: SPRD), China Sunshine Paper (2002.HK), and VanceInfo (NYSE:VIT), Eyang (0117.HK), etc.As an active investor, Legend Capital provides its portfolio companies extensive business resources and tailored services to assist with business development, company image building, and other critical company building activities on Chinese market so as to add value and maximize returns. Legend Capital is proud and thankful that it has the opportunity to blaze a trail with its innovative practice for China's venture capital industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series B, Series A, Series C
- Geography: China, United States, South Korea
Investor stats
- Total investments: 518
- Round size: Series A $2.9M–$93M; Series B $12M–$100M; Series C $15M–$200M
- Lead/follow: 43% lead, 57% follow
- Last fund: Likely still investing — raised $177M in 2021
Portfolio highlights
- Z.ai — The AI Lab behind GLM models, dedicated to inspiring the development of AGI to benefit humanity. https://t.co/gOw7WpwkJt https://t.co/ot9sGVXU8x
- Huixin Bio — Huixin Bio is a developer of exosome purification products and early cancer detection technology.
- Honghu Future Energy — Honghu Fusion is a commercial nuclear fusion startup developing high-temperature superconducting stellarator technology
Nippon Venture Capital ("NVCC"), established in 1996 as one of the few largest Japanese independent venture capital firms, is destined to undertake the unprecedented task of providing full-range venture capital services in cooperation with major Japanese business leaders and leading companies, which have supported and nurtured various newbusinesses on their own, as well as proactively developing new venture enterprises.
Show more...Investment focus
- Industry: Software, Health Care, Medical
- Stage:Venture - Series Unknown, Series A, Series B
- Geography: Japan, United States, Indonesia
Investor stats
- Total investments: 203
- Round size: Series A $1.5M–$45M; Series B $3.3M–$33M; Venture - Series Unknown $457k–$12M
- Lead/follow: 17% lead, 83% follow
- Last fund: Likely still investing — raised $15M in 2023
Portfolio highlights
- KUZEN — KUZEN provides enterprise-grade chatbot technologies, especially the bot framework and NLP, via a visual UI without coding. The company is utilizing technology to develop a system that broadens the scope of dialogue. They use technology to provide their customers with next-generation standard procedures that broaden the possibilities ofconversation, resulting in unprecedented business practices.
- AOI Biosciences — AOI Biosciences is a biotechnology company that creates testing and drug discovery businesses.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
UntroD Capital is an R&D-based innovative technology that specializes in social implementation.
Show more...Investment focus
- Industry: Manufacturing, Biotechnology, Health Care
- Stage:Seed, Venture - Series Unknown, Series A
- Geography: Japan, Singapore, Austria
Investor stats
- Total investments: 148
- Round size: Seed $316k–$6M; Series A $2.1M–$15M; Venture - Series Unknown $438k–$10M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely still investing — fund raised in 2024
Portfolio highlights
- JAOPS — JAOPS develops space mission operations software, tools, training, and services for spacecraft control and simulation.
- Eco-Pork — Eco-Pork is a co-creation solution farm that supports farmers' food productivity improvement. It is connecting the pig and technology, pork ( Pork ) new business ecosystems ( Ecosystem By building a), in the pork growing demand around the world, to get the most out of the food supply capacity is finite.
- Teragen Energy — Teragen Energy develops an energy technology platform based on advanced regenerative solid oxide fuel cells that provide both power generation and energy storage in a single system. The company’s systems generate electricity from external fuels such as natural gas or hydrogen without combustion and can operate in reverse to store power as hydrogen.Teragen designs modular systems that can be scaled from megawatt-scale installations for data centers to deployments for microgrids, renewable projects, and utilities. Its technology is intended to help operators manage variable renewable output, ride through outages, and address daily capacity needs using one device. Teragen focuses on applications including AI and cloud data centers, manufacturing and cold storage facilities, remote communities, and electric grid infrastructure. The platform is positioned to replace separate diesel generators and battery systems by combining fuel-flexible generation and low-cost storage in a compact footprint.
Shenzhen Capital Group Co., Ltd (“SCGC”) is a limited venture capital company established by the Shenzhen Government in 1999. Since its establishment, SCGC has focused on cultivating national industries, shaping national brands, promoting economic transformation, and emerging industries developing. SCGC has registered capital of 5.42 billion RMB,and a total AUM of 338.99 billion RMB. SCGC primarily invests in SMEs, innovative high-tech enterprises, enterprises in emerging industries, and enterprises in start-up period, growth period and in transformation, covering industries supported by national policies, including IT, internet, new media, biopharma, new energy, environmental protection, chemical engineering, new material, high-end equipment manufacturing, consumption goods, modern service, etc. By the end of April 2019, SCGC ranked the first based on the number of portfolio companies and the number of listed portfolio companies: 994 portfolio companies, investments totaling 43.9 billion RMB, 145 of which have been listed in 16 capital markets worldwide.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Software
- Stage:Series A, Series B, Seed
- Geography: China, United States, Japan
Investor stats
- Total investments: 645
- Round size: Seed $1.4M–$29M; Series A $1.6M–$122M; Series B $4.9M–$141M
- Lead/follow: 42% lead, 58% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Prosemi — Pusenmei is a precision micro-resistance current sensor developer company committed to delivering professional and diverse precision micro-resistance current detecting resistors and circuit protection solutions.
- Enrikenuo — Enrikenuo is a biotechnology company that focuses on the research and development of new generation CAR-NK technology based cell drugs.
- Waker Biology — Weike Bio is a gene therapy drug development company.
SND Ventures Group is a venture capital and private equity firm specializing in seed investments.
Show more...Investment focus
- Industry: Manufacturing, Semiconductor, Health Care
- Stage:Series A, Series B, Seed
- Geography: China
Investor stats
- Total investments: 84
- Round size: Series A $1.6M–$21M; Series B $1.4M–$28M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Ruiqi Deep Space — Ruichi Deep Space is an intelligent remote sensing constellation company built on space-based capabilities and driven by AI , aiming to construct a " commercial aerospace" platform.
- Jipai Electromagnetic — Jipai Electromagnetic specializes in the manufacture of automobile components and accessories.
- Sicui Thermal Control — Sicui Thermal Control focuses on the design of next-generation semiconductor and microelectronics thermal management solutions.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Shanlan Capital is a professional fund focused on early and growing health care industry investments with offices in Shanghai and Beijing, focusing on biomedical and medical devices (in vitro diagnostics and gene technology, minimally invasive interventions, implantable devices, minimally invasive High-growth segments such as surgical instrumentsand medical robots, and medical services. It has invested in 15 medical star companies such as Guoke Hengtai, Ricky Surgery, Jingyi Medical, Haipulos, Langhe Medical, etc. The core team of Shanlan Capital is the founder of the medical industry listed company, professional financial and strategic investment. Composition of people, in strategy formulation, talent introduction, technology research and development, market camp..
Show more...Investment focus
- Industry: Health Care, Medical, Medical Device
- Stage:Series A, Series B, Seed
- Geography: China
Investor stats
- Total investments: 35
- Round size: Seed $1.4M–$14M; Series A $1.6M–$16M; Series B $1.5M–$28M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Bochuang Biotechnology — Bochuang Biotechnology is a cutting-edge medical repair product developer that specializes in the controllable electrochemical assembly of biomacromolecules. Bochuang Biotechnology is creating a line of high-end biological tissue functional membranes and derived medical device solutions.
- Insight Technology — Insight Technology is an instrument manufacturer and seller company that specializes in instrument sales, intelligent instrument sales, mechanical equipment research and development, and more.
- Yangshan Medical Technology — Yangshan Medical Technology is a Shanghai-based company specializing in dental surgery robots.
Goldport Capital is a Shenzhen-based asset management company.
Show more...Investment focus
- Industry: Manufacturing, Medical, Semiconductor
- Stage:Series A, Seed, Angel
- Geography: China
Investor stats
- Total investments: 79
- Round size: Seed $1.4M–$15M; Angel $432k–$14M; Series A $1.4M–$15M
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Anxin Medical — Anxin Medical is a company dedicated to the research, development, production, and sales of innovative medical devices. The company focuses on advancing healthcare technology through continuous innovation, integrating cutting-edge science and engineering to create high-quality, reliable, and efficient medical products.
- Deep Carbon Source — Senge Carbon Source makes advanced porous carbon for energy storage devices.
- Feat-Aero Intelligent Technologies — Feat-Aero is a high tech firm designing digital assembly robots and smart tools for aerospace leaders like COMAC and AVIC.
Highlight Capital is an investment firm dedicated to support healthcare companies to generate robust and sustained growth prospect.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, South Korea
Investor stats
- Total investments: 179
- Round size: Seed $10M–$84M; Series A $3.1M–$73M; Series B $7.6M–$70M
- Lead/follow: 35% lead, 65% follow
- Last fund: Likely still investing — raised $563M in 2021
Portfolio highlights
- Genuine Rhythm — Genuine Rhythm is an innovative AI Agent technology developer specializing in bespoke agent creation, advanced algorithm R&D, and rigorous security compliance solutions tailored to diverse enterprise needs.
- Ziwei Technology — Ziwei Technology is a high-tech company making returnable spacecraft.
- Differential Robotics — Differential Robotics is a robotics company providing research, design, and development of aerial robots and intelligent autonomous drones.
SZHTI Group is a company that provides asset management and financing services.
Show more...Investment focus
- Industry: Manufacturing, Electronics, Health Care
- Stage:Series A, Angel, Series B
- Geography: China, Canada, United States
Investor stats
- Total investments: 137
- Round size: Angel $425k–$1.4M; Series A $888k–$16M; Series B $3.2M–$15M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- GeneMind Biosciences — GeneMind Biosciences is a domestic third-generation single-molecule gene sequencing system. GeneMind Biosciences has been fighting to provide better gene sequencing solutions for clinicians and researchers. A Gene sequencer is the crown jewel in the field of gene sequencing. Entrepreneurs will lead their innovations and breakthroughs throughunremitting research and exploration. GeneMind believes that the strong pass of the difficulty is like a wall of iron, yet with firm strides, we are conquering its summit.
- Kiri Innovation — KIRI Innovation develops affordable and innovative 3D scanners. Phiz 3D Scanner is a low cost, high precision laser 3D scanner that works with smartphones. Using today's phone camera and powerful CPU, a laser 3D scanner has never been so affordable and smart.
- Xinhe Robot Technology — Xinhe Robot Technology is an autonomous grain storage robotics manufacturer automating depot leveling and monitoring tasks.
Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Angel
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 153
- Round size: Angel $425k–$15M; Series A $1.5M–$73M; Series B $8.5M–$90M
- Lead/follow: 41% lead, 59% follow
- Last fund: May invest from a new fund soon — raised $430M in 2018
Portfolio highlights
- SeaArt — SeaArt AI is an all-in-one AI creativity community for art, videos, audio, and AI chats, where creators collaborate, spark inspiration, and grow together.
- Zhiran Medical — Zhiran Medical is a medical technology company specializing in the precise detection and treatment of neurological disorders using high-throughput, flexible brain-computer interface technology.
- GigaAI — Excellent Vision is a spatial intelligence company focused to transforming video creation into a 4D world model, enabling AI big models to grasp, generate, and reason about 4D space.
Oriza Holdings is a Chinese management fund that covers equity, debt financing, and investment since 2007.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Canada
Investor stats
- Total investments: 224
- Round size: Seed $4.5M–$30M; Series A $1.5M–$46M; Series B $10M–$100M
- Lead/follow: 27% lead, 73% follow
Portfolio highlights
- BCI-Sonics — BCI-Sonics is an innovative medtech company developing non-invasive brain-computer interface solutions using advanced transcranial focused ultrasound (tFUS) technology. The company builds a next-generation therapeutic platform enabling precise neuromodulation to treat central nervous system disorders. BCI-Sonics develops low-intensity focusedultrasound technology that non-invasively stimulates deep brain regions with high precision. They combine ultrasound engineering and neuroscience to interface safely and effectively with the human brain without surgery. The company is creating an AI ultrasound brain-computer interface platform for therapeutic neuromodulation applications.
- Leadsynbio — Pilot Bio is a bio-manufacturing technology research and development company, focusing on bio-manufacturing of major chemical products, bio-process substitution in heavy-polluting industries, etc., providing users with bio-catalytic synthesis processes, enzyme product research and development, production, sales, and downstream companies with enzymeengineering , Technical service outsourcing and production service outsourcing of strain transformation and metabolic engineering.
- Toto Technology — Borg Technology is a producer of testing and micromachining tools, with an emphasis on optical and precision optical devices.
ANRI is a Japanese venture capital firm that mainly invests in seed and early-stage startups.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Seed, Series A, Venture - Series Unknown
- Geography: Japan, United States, Indonesia
Investor stats
- Total investments: 315
- Round size: Seed $268k–$9.9M; Series A $967k–$41M; Venture - Series Unknown $616k–$9.1M
- Lead/follow: 24% lead, 76% follow
- Last fund: Likely still investing — raised $102M in 2022
Portfolio highlights
- Any Style — Any Style develops a messaging app from voice actors that regularly sends messages via subscription. It also engages in the planning and production of audio content and the VTuber production business.
- Arrowsmith — Arrowsmith is committed to unlocking the full potential of bacteriophages to revolutionize the treatment of bacterial infectious diseases. Through transformative science, Arrowsmith strive to create a world free from the pain and fear caused by antimicrobial resistance.
- Typewriter Therapeutics — Typewriter Therapeutics, Inc. develops mRNA-based gene therapies using a gene writing, or gene writing, platform for precise insertion of therapeutic genes into the genome. The company builds on transposon-based technologies originating from research by Professor Emeritus Haruhiko Fujiwara at the University of Tokyo. Its programs focus on all‑RNA,nonviral gene writing systems that repurpose natural genetic elements to address severe genetic disorders with limited treatment options. Typewriter Therapeutics conducts research and development across its U.S. and Japan operations and collaborates with investors and partners to advance genetic medicine candidates toward the clinic.
Keio Innovation Initiative (KII) is a venture capital established by Keio University. In order to make more effective use of the research results of Keio University, we aim to contribute to the development of society by creating investment for venture companies that utilize research results and creating new industries.The key to thinking aboutJapan's future growth strategy is to utilize advanced research results of the university. In addition to GDP, in addition to GDP, Japan is the world's third largest R & D exporter in R & D expenses, but as the low growth rate shows, it has a problem in investment efficiency in research and development. There are also reports on the entrepreneurial spirit that is indispensable for creating new industries, with the lowest entrepreneurial activity rate among developed countries.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Seed, Venture - Series Unknown
- Geography: Japan, United Kingdom
Investor stats
- Total investments: 91
- Round size: Seed $826k–$14M; Series A $2.2M–$41M; Venture - Series Unknown $1.6M–$12M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $94M in 2020
Portfolio highlights
- ElleThermo — elleThermo aims to implement Semiconductor-Sensitised Thermal Cells (STCs), an energy conversion technology that can generate electricity from unused waste heat above room temperature.
- Starlight Engine — Starlight Engine develops and commercializes fusion energy power plant technologies.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
Fortune Capital, established in April, 2000, is one of the earliest market-oriented venture capital firms in China. For the past 14 years, Fortune Capital focus its investments on leading companies in four key sectors: TMT (Media oriented), Consumer Goods/Services, Modern Agriculture and Clean Tech.Fortune Capital is ranked among thehighest performing VC/PE firms in China and selected as "Vice President of Venture Capital Committee of IAC," "Vice President of Shenzhen VC Association," "Vice President of Shenzhen Chamber of International Investment & Funding," etc.In addition to providing capitals, Fortune Capital provides its investee companies with personalized value-added services.
Show more...Investment focus
- Industry: Manufacturing, Software, Information Technology
- Stage:Series A, Series B, Seed
- Geography: China, Japan, United States
Investor stats
- Total investments: 324
- Round size: Seed $462k–$73M; Series A $1.5M–$70M; Series B $3M–$60M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $860M in 2021
Portfolio highlights
- Sandstone — SandStone is a product, solution and service provider focused on next-generation data storage (ServerSAN), which is dedicated to helping users cope with data storage, traffic and data management complexity, helping users build storage virtualization and Computation of virtualization as the core cloud computing infrastructure environment, andgradually provide data processing, mining, analysis and intelligence in the field of big data professional systems and services.
- Sungen Biomedical — Sungen Biomedical is an innovative antibody drug R&D enterprise. It has established international standard technology platforms and original biological macromolecular R&D pipelines. Their focus includes therapeutic drugs for cardiovascular and cerebrovascular diseases, tumors, and more.
- NeueHCT — Horizon Continental Technology is a joint venture between Continental Group and Horizon Robotics
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!SBI Investment supports the business development and growth of private venture companies through fund investment. It manages and manages venture capital funds under the management philosophy of becoming a leading company responsible for the creation and development of core industries in the 21st century as a "new industry creator".SBIInvestment has invested in a total of 986 companies in the past, of which 169 (17.1% of investment companies) have exited through IPO or M & A.
Show more...Investment focus
- Industry: Software, Information Technology, Financial Services
- Stage:Series B, Series A, Venture - Series Unknown
- Geography: Japan, United States, South Korea
Investor stats
- Total investments: 454
- Round size: Series A $1.9M–$28M; Series B $4.5M–$60M; Venture - Series Unknown $1.3M–$20M
- Lead/follow: 27% lead, 73% follow
- Last fund: May invest from a new fund soon — raised $77M in 2020
Portfolio highlights
- LQUOM — QWAVE offers cryptography communication technology.
- Alxtal — Alxtal is a tech company who optimize the development, design, and manufacturing processes of the manufacturing industry with IT and AI.
- Direava — Direava is a medical device company that manufactures, sells, leases, and maintains medical equipments along with consulting services.
Marathon Venture Partners is an international VC fund that focuses on early and growth stage companies in healthcare and Fintech industry.
Show more...Investment focus
- Industry: Health Care, Medical, Biotechnology
- Stage:Series A, Series B, Seed
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 63
- Round size: Seed $7M–$13M; Series A $1.5M–$29M; Series B $14M–$142M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Fungifuture — Fungifuture is a synthetic biomaterials company specializing in the research and development and production of fungal fiber materials.
- Ruize Health — Ruize Health is a commercial insurance company that focuses on health consumption and commercial insurance.
- Fuxin Technology Innovation — Fuxin Kechuang is a high-tech company that specializes in offering detailed information solutions for the medical and healthcare industries. The business offers creative software solutions and services to a range of healthcare organizations, actively supports the digital transformation of healthcare, and uplifts the medical sector. The company hasgained recognition and has become a partner of big and medium-sized medical institutions and healthcare institutions by relying on its technological research and development power, service capabilities, and ecosystem of medical and health software.
Mizuho is the venture capital firm affiliated to Mizuho Bank, the second-largest Japanese bank in terms of assets. The firm has headquarters in Tokyo.The firm has ¥49.6 billion JPY under management, focusing on information technology and biotechnology investments. Over 600 Mizuho companies have gone public. According to Nikkei, Mizuho is thefifth-largest venture capital firm in Japan.Mizuho Capital was formed in 2002 by the merger of Fujigin Capital, Tokyo Venture Capital and IBJ Investment. Three firms were subsidiaries of Fuji Bank, Dai-Ichi Kangyo Bank and the Industrial Bank of Japan respectively.
Show more...Investment focus
- Industry: Information Technology, Software, Artificial Intelligence
- Stage:Series A, Venture - Series Unknown, Series B
- Geography: Japan, United States, Singapore
Investor stats
- Total investments: 545
- Round size: Series A $1.4M–$32M; Series B $2.4M–$47M; Venture - Series Unknown $661k–$10M
- Lead/follow: 5% lead, 95% follow
- Last fund: May invest from a new fund soon — raised $92M in 2020
Portfolio highlights
- CaTe — CaTe is based in Tokyo. CaTe develops and manufactures a Digital Therapeutic (DTx) for remote cardiac rehabilitation. Their invention allows heart disease patients to safely and successfully complete cardiac rehabilitation utilizing standing exercise in a confined space, such as at home, without the use of ergometers or similar instruments.
- AIONA — AIONA uses AI to produce high-quality products and provides everyone with access to knowledge.
- Yoom — Yoom is a consulting company that offers system development services on AI, IoT, data solutions, and cloud integration.
UTEC-The University of Tokyo Edge Capital Partners Co., Ltd.. UTEC is a seed/early stage technology focused venture capital firm associated with The University of Tokyo.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Series B
- Geography: Japan, United States, India
Investor stats
- Total investments: 212
- Round size: Seed $624k–$12M; Series A $2.3M–$18M; Series B $2.8M–$20M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely actively investing — fresh fund, raised $326M in 2025
Portfolio highlights
- Mujin — At Mujin, we design automation platforms to enhance any robot, enable advanced capabilities and lower operating costs.
- X Mile — Corporate Site:https://www.xmile.co.jp/ Service Site:https://x-work.jp/
- RegCell — RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer .
Huaige Capital is a venture capital focusing on healthcare sector.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Series A, Angel, Seed
- Geography: China
Investor stats
- Total investments: 23
- Round size: Angel $455k–$14M; Series A $3M–$36M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- Heerkang — Heerkang is a medical technology company that provides medical device research and sales, and health consultation services.
- Xianyan Biopharma — Xianyan Biopharma is a company that focuses on core technology innovation and new medication development for oligonucleotides, and it has a top-tier R&D staff.
- Yili Pharmaceutical — Yili Pharmaceutical is a pharmaceutical R&D company that mainly engages in biochemical product technology R&D, medical research and experimental development, engineering and technology research and experimental development, and software development.
Tsinghua Innovation Ventures is an investment management firm.
Show more...Investment focus
- Industry: Manufacturing, Medical, Health Care
- Stage:Venture - Series Unknown, Series A, Seed
- Geography: China
Investor stats
- Total investments: 97
- Round size: Seed $832k–$15M; Series A $1.6M–$23M
- Lead/follow: 21% lead, 79% follow
Portfolio highlights
- Deep Cell — Deep Cell is a Chinese AI driven drug discovery and virtual cell modeling startup. The company integrates artificial intelligence with multi scale molecular physics to construct explainable virtual cell world models, aiming to revolutionize paradigm shifting drug designs and simulate cellular responses to complex diseases.
- Brighten Data — Brighten Data is an AI-native platform that provides one-stop AI data intelligence products and large model application services.
- FangQing Technology — Fangqing Technology is a company mainly engaged in multiple areas of the communications equipment and software industry. Its core business activities include software development and sales, software outsourcing services, information system integration services, and computer system services.
Apricot Capital is an investment firm focused on investing in companies in the early and growing stages of the healthcare industry, including biopharmaceuticals, life sciences, medical devices, medical services, and diagnostics.Founded in 2015, Apricot Capital consists of more than 20 professionals and consultants with experience in thehealthcare industry. Its professional background includes life sciences, medicine, finance and law.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: China, United States, Hong Kong
Investor stats
- Total investments: 46
- Round size: Seed $10M–$41M; Series A $3M–$54M; Series B $14M–$58M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- iRegene — iRegene researches and develops pharmaceutical therapy for neurodegenerative and rare diseases.
- Vibrant — Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects tocontinuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China.
- Microtide Biotechnology — Microtide Biotechnology is an innovative company specializing in the field of in vivo cell therapy. The company is dedicated to advancing next-generation biomedical technologies that harness the body’s own cellular mechanisms for disease treatment, focusing on developing safe, effective, and precise therapeutic solutions to improve patient outcomesand redefine the future of regenerative medicine.
CDH Investments is an international alternative asset fund manager with over $27 billion of assets under management. CDH Investments was established in 2002 by the former private equity group of China International Capital Corporation and is managed by an experienced team of senior private equity professionals who have worked together for manyyears focusing all their professional time on investing in China. CDH has consistently delivered superior returns relative to industry peers and is well positioned to continue to generate superior returns due to the team's proven investment experience and expertise investing in China.
Show more...Investment focus
- Industry: Manufacturing, Health Care, Biotechnology
- Stage:Series A, Series B, Series C
- Geography: China, United States, Canada
Investor stats
- Total investments: 298
- Round size: Series A $7.3M–$100M; Series B $14M–$142M; Series C $30M–$220M
- Lead/follow: 47% lead, 53% follow
Portfolio highlights
- HitGen — HitGen is provides biological reagents and services to support drug discovery research.
- PaXini Tech — All Scenario Application—Haptic Digitization and Tactile Technology
- Eyegood Ophthalmic Hospital — Eyegood Ophthalmic Hospital is a ophthalmology hospital.
Catalysing smart monies into Singapore-based, early-stage technology startups.
Show more...Investment focus
- Industry: Biotechnology, Artificial Intelligence, Health Care
- Stage:Seed, Series A, Series B
- Geography: Singapore, United States, Hong Kong
Investor stats
- Total investments: 150
- Round size: Seed $767k–$6.8M; Series A $2.4M–$21M; Series B $5M–$45M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Nexstrom — Nexstrom develops wafer-scale 2D semiconductor technology and manufacturing systems for next-generation computing and AI infrastructure.
- Respiree — They offer platforms that are able to report clinical deterioration and provide recommended interventions with post-monitoring.They work in the health care industry, just like you. We take the time to get to know you, and we always keep your best interests in mind when adding and adjusting products in our catalog.
- Protuoso Biosciences — Protuoso Bio is a pioneering biotechnology company developing Next-Gen MUXBODIES for Complex Diseases. We leverage AI-driven protein engineering and synthetic biology to advance innovative oncology drug research.
FFG Venture Business Partners is a large-scale enterprise that offers in traditional regional bank venture capital.
Show more...Investment focus
- Industry: Software, Health Care, Artificial Intelligence
- Stage:Series A, Seed, Series B
- Geography: Japan, Indonesia, United States
Investor stats
- Total investments: 87
- Round size: Seed $1M–$50M; Series A $1.2M–$37M; Series B $4.3M–$113M
- Lead/follow: 10% lead, 90% follow
- Last fund: May invest from a new fund soon — raised $691M in 2020
Portfolio highlights
- MW — MW is a smart home solution company that develops smart residential physical AI, robotics, and home design services.
- InsightX — InsightX is a technology platform focused on empowering businesses by simplifying complex processes and enabling smarter, more personalized user experiences.
- Neusignal Therapeutics — Neusignal Therapeutics is a medical company that develops therapeutic medicines for dementia and psychiatric illnesses.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Medical Device VC Funds in Asia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 VC funds investing in Asia Medical Device startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!